Anne Hanson-Borjesson

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

New therapies and ongoing clinical trials in Alzheimer's disease

New therapies and ongoing clinical trials in Alzheimer's disease

Journal: Lakartidningen

Published: May 20, 2026

Meat Consumption and Cognitive Health by APOE Genotype.

Meat Consumption and Cognitive Health by APOE Genotype.

Journal: JAMA network open

Published: March 19, 2026

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

Journal: EBioMedicine

Published: February 20, 2025

Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL.

Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL.

Journal: JAMA neurology

Published: November 29, 2024

New Alzheimer's treatments - a need for national preparations and coordination

New Alzheimer's treatments - a need for national preparations and coordination

Journal: Lakartidningen

Published: November 27, 2024

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial.

Journal: Nature medicine

Published: November 01, 2023

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

Journal: Nature medicine

Published: October 16, 2023

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter.

Journal: Translational neurodegeneration

Published: January 23, 2023

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.

Journal: Nature medicine

Published: September 01, 2022

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.

Journal: Frontiers in neurology

Published: December 03, 2019

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

Journal: Neurobiology of aging

Published: December 14, 2018

Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly.

Low Cerebrospinal Fluid Aβ42 and Aβ40 are Related to White Matter Lesions in Cognitively Normal Elderly.

Journal: Journal of Alzheimer's disease : JAD

Published: April 05, 2018

Showing 1-12 of 45

Last Updated: 09/26/2026